Back to User profile » Dr Michael Offin
Paper published by Dr Michael Offin:
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Liu D, Offin M, Harnicar S, Li BT, Drilon A
Therapeutics and Clinical Risk Management 2018, 14:1247-1252
Published Date: 20 July 2018